Liberona A, Jones N, Zuniga K, Garrido V, Zelada M, Silva H
Int J Mol Sci. 2024; 25(20).
PMID: 39456983
PMC: 11508575.
DOI: 10.3390/ijms252011204.
Lv Y, Wen L, Hu W, Deng C, Ren H, Bao Y
Metab Brain Dis. 2023; 39(1):147-171.
PMID: 37542622
DOI: 10.1007/s11011-023-01271-x.
Elsheikh S, Muller D, Pouget J
Methods Mol Biol. 2022; 2547:389-425.
PMID: 36068471
DOI: 10.1007/978-1-0716-2573-6_14.
Di Carlo P, Punzi G, Ursini G
Psychiatr Genet. 2019; 29(5):200-210.
PMID: 31465000
PMC: 7386257.
DOI: 10.1097/YPG.0000000000000237.
Gillespie A, Samanaite R, Mill J, Egerton A, MacCabe J
BMC Psychiatry. 2017; 17(1):12.
PMID: 28086761
PMC: 5237235.
DOI: 10.1186/s12888-016-1177-y.
Brain-Derived Neurotrophic Factor Gene Val66Met Polymorphism and Risk of Schizophrenia: A Meta-analysis of Case-Control Studies.
Kheirollahi M, Kazemi E, Ashouri S
Cell Mol Neurobiol. 2015; 36(1):1-10.
PMID: 26134309
PMC: 11482494.
DOI: 10.1007/s10571-015-0229-z.
Evidence for Association between the Brain-Derived Neurotrophic Factor Gene and Panic Disorder: A Novel Haplotype Analysis.
Han E, Kim Y, Hwang J, Kim S, Lee H, Yoon H
Psychiatry Investig. 2015; 12(1):112-7.
PMID: 25670953
PMC: 4310908.
DOI: 10.4306/pi.2015.12.1.112.
Genetic variations of PIP4K2A confer vulnerability to poor antipsychotic response in severely ill schizophrenia patients.
Kaur H, Jajodia A, Grover S, Baghel R, Gupta M, Jain S
PLoS One. 2014; 9(7):e102556.
PMID: 25025909
PMC: 4099378.
DOI: 10.1371/journal.pone.0102556.
Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis.
Murphy B, Pang T, Hannan A, Proffitt T, McConchie M, Kerr M
Schizophr Res Treatment. 2014; 2014:719395.
PMID: 24672724
PMC: 3941155.
DOI: 10.1155/2014/719395.
Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients.
Nikolac Perkovic M, Nedic Erjavec G, Zivkovic M, Sagud M, Uzun S, Mihaljevic-Peles A
Psychopharmacology (Berl). 2014; 231(18):3757-64.
PMID: 24595507
DOI: 10.1007/s00213-014-3515-4.
Association of the brain-derived neurotrophic factor gene G196A rs6265 polymorphisms and the cognitive function and clinical symptoms of schizophrenia.
Zhai J, Yu Q, Chen M, Gao Y, Zhang Q, Li J
Int J Clin Exp Pathol. 2013; 6(8):1617-23.
PMID: 23923080
PMC: 3726978.
BDNF and schizophrenia: from neurodevelopment to neuronal plasticity, learning, and memory.
Nieto R, Kukuljan M, Silva H
Front Psychiatry. 2013; 4:45.
PMID: 23785335
PMC: 3683823.
DOI: 10.3389/fpsyt.2013.00045.
The promise and reality of pharmacogenetics in psychiatry.
Zandi P, Judy J
Psychiatr Clin North Am. 2010; 33(1):181-224.
PMID: 20159346
PMC: 3178049.
DOI: 10.1016/j.psc.2009.12.001.
Genetic variants in the BDNF gene and therapeutic response to risperidone in schizophrenia patients: a pharmacogenetic study.
Xu M, Li S, Xing Q, Gao R, Feng G, Lin Z
Eur J Hum Genet. 2010; 18(6):707-12.
PMID: 20087404
PMC: 2987331.
DOI: 10.1038/ejhg.2009.238.
Brain derived neurotropic factor in first-episode psychosis.
Buckley P, Pillai A, Evans D, Stirewalt E, Mahadik S
Schizophr Res. 2007; 91(1-3):1-5.
PMID: 17306505
PMC: 1933504.
DOI: 10.1016/j.schres.2006.12.026.
Imaging genomics and response to treatment with antipsychotics in schizophrenia.
Blasi G, Bertolino A
NeuroRx. 2006; 3(1):117-30.
PMID: 16490418
PMC: 3593360.
DOI: 10.1016/j.nurx.2005.12.001.